Takeda Pharmaceutical (TAK) Long-Term Debt Repayments (2019 - 2025)
Historic Long-Term Debt Repayments for Takeda Pharmaceutical (TAK) over the last 7 years, with Q4 2025 value amounting to -$64.1 million.
- Takeda Pharmaceutical's Long-Term Debt Repayments rose 994.99% to -$64.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$289.0 million, marking a year-over-year increase of 375.88%. This contributed to the annual value of -$296.6 million for FY2025, which is 2164.97% up from last year.
- Latest data reveals that Takeda Pharmaceutical reported Long-Term Debt Repayments of -$64.1 million as of Q4 2025, which was up 994.99% from -$68.6 million recorded in Q3 2025.
- In the past 5 years, Takeda Pharmaceutical's Long-Term Debt Repayments ranged from a high of -$64.1 million in Q4 2025 and a low of -$147.4 million during Q4 2023
- Over the past 5 years, Takeda Pharmaceutical's median Long-Term Debt Repayments value was -$80.7 million (recorded in 2022), while the average stood at -$83.7 million.
- Per our database at Business Quant, Takeda Pharmaceutical's Long-Term Debt Repayments plummeted by 8080.24% in 2023 and then surged by 5170.91% in 2024.
- Quarter analysis of 5 years shows Takeda Pharmaceutical's Long-Term Debt Repayments stood at -$82.4 million in 2021, then increased by 1.11% to -$81.5 million in 2022, then tumbled by 80.8% to -$147.4 million in 2023, then skyrocketed by 51.71% to -$71.2 million in 2024, then increased by 9.95% to -$64.1 million in 2025.
- Its Long-Term Debt Repayments was -$64.1 million in Q4 2025, compared to -$68.6 million in Q3 2025 and -$84.4 million in Q2 2025.